Logotype for Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International (KNSA) investor relations material

Kiniksa Pharmaceuticals International Wells Fargo 20th Annual Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kiniksa Pharmaceuticals International plc
Wells Fargo 20th Annual Healthcare Conference 2025 summary4 Sep, 2025

Company overview and growth trajectory

  • Focused on value creation with a commercialized product, Arclis, showing strong revenue growth since its 2021 launch, reaching $156.8M in Q2 and guiding $625M–$640M for 2025.

  • Penetration into the target patient population is about 15%, indicating significant room for expansion.

  • Development pipeline includes KPL-387 (monthly liquid formulation, auto-injector) in Phase II/III, aiming for market entry in 2028–2029, and 1161, a quarterly antibody targeting IL-1 alpha and beta.

Arclis commercialization and market dynamics

  • Arclis is the first and only FDA-approved therapy for recurrent pericarditis, with a broad label and growing prescriber base (over 3,475 prescribers as of Q2).

  • Patient education, physician outreach, and digital strategies, including AI, are driving adoption.

  • Medicare Part D changes led to a one-time patient bolus, with ongoing monitoring of affordability and access.

  • Average treatment duration is 30 months, with 45% of patients restarting therapy after stopping.

Pipeline development and clinical strategy

  • KPL-387 targets monthly dosing with strong physician and patient preference; Phase II data expected in 2026, with market entry targeted for 2028–2029.

  • Phase I data show sustained drug levels and a safety profile consistent with IL-1 inhibition.

  • 1161 is in preclinical development, aiming for quarterly dosing and broader auto-inflammatory indications.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Kiniksa Pharmaceuticals International earnings date

Logotype for Kiniksa Pharmaceuticals International plc
Q3 202528 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Kiniksa Pharmaceuticals International earnings date

Logotype for Kiniksa Pharmaceuticals International plc
Q3 202528 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines. The company's work targets debilitating diseases with significant unmet medical needs, particularly within cardiovascular and autoimmune disorders. Kiniksa's portfolio includes products and candidates based on strong biological rationale or validated mechanisms, offering potential differentiation in treatment approaches. The company is known for its flagship product, ARCALYST, which is used to treat certain inflammatory cardiovascular conditions. The company is headquarted in London, UK, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage